Skip to main content
Chiome Bioscience Inc. logo

Chiome Bioscience Inc. — Investor Relations & Filings

Ticker · 4583 ISIN · JP3205350006 T Professional, scientific and technical activities
Open in API
Filings indexed 70 across all filing types
Latest filing 2024-05-14 Interim / Quarterly Rep…
Country JP Japan
Listing T 4583

About Chiome Bioscience Inc.

https://www.chiome.co.jp/

Chiome Bioscience Inc. is a clinical-stage biotechnology company specializing in the research and development of antibody-based therapeutics. The company leverages its proprietary ADLib® system, an innovative antibody generation technology, to discover and develop fully human monoclonal antibodies. Its primary mission is to address unmet medical needs by creating novel antibody drugs. The company's operations focus on the early stages of the drug discovery and development process, including initial research and early-phase clinical trials.

Recent filings

Filing Released Lang Actions
四半期報告書－第21期第1四半期(2024/01/01－2024/03/31)
Interim / Quarterly Report Classification · 1% confidence The document is a 'Quarterly Report' (四半期報告書) for Chiome Bioscience Inc., covering the period from January 1, 2024, to March 31, 2024. It contains detailed financial statements, management analysis, and corporate information, which aligns with the definition of an Interim/Quarterly Report (IR). Q1 2024
2024-05-14 Japanese
確認書
Report Publication Announcement Classification · 1% confidence The document is titled "第１四半期報告書" (First Quarter Report) and contains a confirmation statement ("確認書") regarding the appropriateness of the contents of the company's First Quarter Report for the period ending March 31, 2024, submitted to the Kanto Local Finance Bureau under the Financial Instruments and Exchange Act. This structure, focusing on a quarterly report and a formal confirmation/attestation regarding its accuracy, strongly indicates a comprehensive quarterly financial filing. Reviewing the definitions: - 10-K is for Annual Reports. - ER (Earnings Release) is usually just the initial highlights. - IR (Interim/Quarterly Report) is the comprehensive report for a period shorter than a year. Since this document explicitly deals with the contents and confirmation of the 'First Quarter Report' (第１四半期報告書), it aligns best with the definition of a comprehensive quarterly financial report, which corresponds to the Interim / Quarterly Report (IR) category.
2024-05-14 Japanese
臨時報告書
AGM Information Classification · 1% confidence The document is titled "臨時報告書" (Extraordinary Report) and explicitly states in Section 1 that it is being submitted because resolutions were passed at the company's 20th Annual General Meeting (定時株主総会) held on March 26, 2024, in accordance with the Financial Instruments and Exchange Act. The content details the resolutions passed, including capital reduction and the election of an auditor, along with the voting results. This structure—reporting the results of a shareholder meeting—aligns perfectly with the definition of reporting voting results from a general meeting. The closest specific code is DVA (Declaration of Voting Results & Voting Rights Announcements). Although it is an 'Extraordinary Report' (which might suggest RNS), the specific content is the declaration of voting results from the AGM, making DVA the most accurate classification.
2024-03-26 Japanese
内部統制報告書－第20期(2023/01/01－2023/12/31)
Governance Information Classification · 1% confidence The document is explicitly titled "内部統制報告書" (Internal Control Report) in the header and within the table structure. It references the legal basis as Article 24-4-4, Paragraph 1 of the Financial Instruments and Exchange Act (金融商品取引法第24条の４の４第１項), which mandates the filing of an Internal Control Report by listed companies in Japan. The content discusses the framework, scope, criteria, and conclusion regarding the effectiveness of internal controls over financial reporting as of the fiscal year-end (2023年12月31日). This directly corresponds to the requirements for an Audit Report/Information filing, specifically focusing on internal controls, which aligns best with the 'AR' (Audit Report / Information) category, as it is a formal report on internal control effectiveness, distinct from a full Annual Report (10-K) or a simple Earnings Release (ER).
2024-03-26 Japanese
確認書
Regulatory Filings Classification · 1% confidence The document is titled '確認書' (Confirmation Letter) and explicitly states it is filed under the Financial Instruments and Exchange Act to confirm the accuracy of the contents of the Annual Securities Report (有価証券報告書). According to the 'CERTIFICATION RULE', documents that are primarily officer certifications or attestations, even if they reference a specific report, should be classified as Regulatory Filings (RNS). FY 2023
2024-03-26 Japanese
有価証券報告書－第20期(2023/01/01－2023/12/31)
Annual Report Classification · 1% confidence The document is a '有価証券報告書' (Yuuka Shouken Houkokusho), which is the standard Japanese annual securities report required under the Financial Instruments and Exchange Act. It contains comprehensive financial statements, business analysis, and corporate information for the fiscal year ending December 31, 2023. This corresponds to the 10-K filing category in the provided schema. FY 2023
2024-03-26 Japanese

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.